Differential requirement for wild-type Flt3 in leukemia initiation among mouse models of human leukemia

Experimental Hematology

Volumn 42, Issue 3, 2014, Pages 192-203.e1

  Kamezaki, Kenjiro ^a   Luchsinger, Larry L ^a   Snoeck, Hans Willem ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; INTERLEUKIN 3; INTERLEUKIN 6; STEM CELL FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINEAGE; COLONY FORMATION; COLONY FORMING UNIT; CONTROLLED STUDY; ENZYME RECONSTITUTION; GENE REARRANGEMENT; HEMATOPOIESIS; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SURVIVAL RATE;

ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, KNOCKOUT; NEOPLASTIC STEM CELLS; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84897780344     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.11.008     Document Type: Article

References (41)

1. Chen J., Odenike O., Rowley J.D. Leukaemogenesis: more than mutant genes. Nat Rev Cancer 2010, 10:23-36.
2. Meshinchi S., Appelbaum F.R. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res 2009, 15:4263-4269.
3. Kikushige Y., Yoshimoto G., Miyamoto T., et al. Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival. J Immunol 2008, 180:7358-7367.
4. Mackarehtschian K., Hardin J.D., Moore K.A., Boast S., Goff S.P., Lemischka I.R. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 1995, 3:147-161.
5. Buza-Vidas N., Cheng M., Duarte S., Charoudeh H.N., Jacobsen S.E., Sitnicka E. FLT3 receptor and ligand are dispensable for maintenance and posttransplantation expansion of mouse hematopoietic stem cells. Blood 2009, 113:3453-3460.
6. Kindler T., Lipka D.B., Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010, 116:5089-5102.
7. Fathi A., Levis M. FLT3 inhibitors: a story of the old and the new. Curr Opin Hematol 2011, 18:71-76.
8. Armstrong S.A., Kung A.L., Mabon M.E., et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer cell 2003, 3:173-183.
9. Armstrong S.A., Staunton J.E., Silverman L.B., et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002, 30:41-47.
10. Stam R.W., den Boer M.L., Schneider P., et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 2005, 106:2484-2490.
11. Brown P., Levis M., Shurtleff S., Campana D., Downing J., Small D. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 2005, 105:812-820.
12. Becker M.W., Jordan C.T. Leukemia stem cells in 2010: current understanding and future directions. Blood reviews 2011, 25:75-81.
13. Ito K., Bernardi R., Morotti A., et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008, 453:1072-1078.
14. Sloma I., Jiang X., Eaves A.C., Eaves C.J. Insights into the stem cells of chronic myeloid leukemia. Leukemia 2010, 24:1823-1833.
15. Palmqvist L., Argiropoulos B., Pineault N., et al. The Flt3 receptor tyrosine kinase collaborates with NUP98-HOX fusions in acute myeloid leukemia. Blood 2006, 108:1030-1036.
16. Albouhair S., Morgado E., Lavau C. Flt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes. PloS One 2013, 8:e72261.
17. Morgado E., Albouhair S., Lavau C. Flt3 is dispensable to the Hoxa9/Meis1 leukemogenic cooperation. Blood 2007, 109:4020-4022.
18. Zeisig B.B., Milne T., Garcia-Cuellar M.P., et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol 2004, 24:617-628.
19. Kroon E., Krosl J., Thorsteinsdottir U., Baban S., Buchberg A.M., Sauvageau G. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 1998, 17:3714-3725.
20. Wong P., Iwasaki M., Somervaille T.C., So C.W., Cleary M.L. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev 2007, 21:2762-2774.
21. Krivtsov A.V., Twomey D., Feng Z., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442:818-822.
22. Cozzio A., Passegue E., Ayton P.M., Karsunky H., Cleary M.L., Weissman I.L. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003, 17:3029-3035.
23. Guibal F.C., Alberich-Jorda M., Hirai H., et al. Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood 2009, 114:5415-5425.
24. Somervaille T.C., Cleary M.L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006, 10:257-268.
25. Pear W.S., Miller J.P., Xu L., et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998, 92:3780-3792.
26. Somervaille T.C., Matheny C.J., Spencer G.J., et al. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 2009, 4:129-140.
27. Yan M., Kanbe E., Peterson L.F., et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med 2006, 12:945-949.
28. Yoshimoto G., Miyamoto T., Jabbarzadeh-Tabrizi S., et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 2009, 114:5034-5043.
29. Mizuki M., Schwable J., Steur C., et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 2003, 101:3164-3173.
30. Yu B.D., Hess J.L., Horning S.E., Brown G.A., Korsmeyer S.J. Altered Hox expression and segmental identity in Mll-mutant mice. Nature 1995, 378:505-508.
31. Thiel A.T., Huang J., Lei M., Hua X. Menin as a hub controlling mixed lineage leukemia. BioEssays: news and reviews in molecular, cellular and developmental biology 2012, 34:771-780.
32. Wang Y., Krivtsov A.V., Sinha A.U., et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010, 327:1650-1653.
33. Faber J., Krivtsov A.V., Stubbs M.C., et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 2009, 113:2375-2385.
34. Hawley T.S., Fong A.Z., Griesser H., Lyman S.D., Hawley R.G. Leukemic predisposition of mice transplanted with gene-modified hematopoietic precursors expressing flt3 ligand. Blood 1998, 92:2003-2011.
35. Krivtsov A.V., Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nature reviews Cancer 2007, 7:823-833.
36. Jiang X., Huang H., Li Z., et al. Blockade of miR-150 maturation by MLL-Fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell 2012, 22:524-535.
37. Choudhary C., Brandts C., Schwable J., et al. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 2007, 110:370-374.
38. Choudhary C., Olsen J.V., Brandts C., et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 2009, 36:326-339.
39. Schmidt-Arras D., Bohmer S.A., Koch S., et al. Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality. Blood 2009, 113:3568-3576.
40. Avagyan S., Glouchkova L., Choi J., Snoeck H.W. A quantitative trait locus on chromosome 4 affects cycling of hematopoietic stem and progenitor cells through regulation of TGF-beta 2 responsiveness. J Immunol 2008, 181:5904-5911.
41. Avagyan S., Aguilo F., Kamezaki K., Snoeck H.W. Quantitative trait mapping reveals a regulatory axis involving peroxisome proliferator-activated receptors, PRDM16, transforming growth factor-beta2 and FLT3 in hematopoiesis. Blood 2011, 118:6078-6086.